Скачать с ютуб Medications for Anxiety Disorders and PTSD | Mental Health Professional Webinar в хорошем качестве

Medications for Anxiety Disorders and PTSD | Mental Health Professional Webinar

This webinar will describe current medication therapies for anxiety disorders and PTSD, focusing on FDA-approved and evidence-based approaches. Experimental drugs in development will also be reviewed, as well as the neurobiological rationale for their use. The risk/benefit profile and limitations of pharmacotherapies will be discussed. ADAA is proud to offer resources for mental health professionals. Find additional tools and information: - Visit the ADAA website: https://adaa.org/professionals - View upcoming professional webinars and events: https://adaa.org/calendar - Learn more in ADAA's PTSD brochure: https://adaa.org/sites/default/files/... - Subscribe to ADAA’s bi-weekly professional newsletter: https://adaa.informz.net/adaa/pages/I... - The Anxiety and Depression Association of America (ADAA), a non-profit organization, leads in education, training, and research for anxiety disorders, depression, PTSD, OCD, and co-occurring disorders. ADAA also provides free evidence-based mental health information and resources to the public. 0:00 Introduction 1:30 Anxiety Disorders: Overview • Anxiety disorders are among the most prevalent mental disorders 2:45 Disability-adjusted life years lost for anxiety disorders 4:23 Unmet Needs in Drug Therapeutics 6:39 Trends in Outpatient Benzodiazepine Prescribing in the U.S. 7:35 Benzodiazepines for Anxiety Disorders 9:45 FDA Boxed Warning Update on Benzodiazeping (Sept 23, 2020) 10:42 Benzodiazepines in PTSD: Commonly used but Little Evidence • Preclinically may interfere with extinction of fear conditioning and/or potentiate acquisition of fear response 11:34 Alternatives to Benzodiazepines Nightime Dosing for Insomnia Daytime and Evening Dosing for . Non-BZD Hypnotics 14:02 Relationship Between GABA and Neuroactive Stere 15:27 Zuranolone (SAGE-217) - Phase 2 Trial in MDD 16:43 Overlapping Symptoms of GAD and Major Depressive Disorder Generalized Anxiety Disorder Major Depressive Disorder 18:51 Treatment Algorithm for GAD 19:28 Pregabalin for Rapid Reduction of Anxiety in 19:53 Notable Failures of Novel Drugs for GAD 20:48 Troriluzole for GAD: Phase 3 trial (n=402) • Third-generation prodrug and new chemical entity that modulates glutamate and normalizes synaptic levels of glutamate. 21:07 The Glutamate Tripartite Synapse: Multiple Targets for Drug Discovery 22:08 Pharmacotherapy for SAD 22:44 Paroxetine Treatment of Social Anxiety Disorder A Pivotal RCT 24:45 Ketamine for Social Anxiety Disorder: Randomized Control Crossover Study 25:24 Pharmacotherapy for PTSD . 4 medications with at least moderate quality evidence criteria for efficacy 25:47 Prolonged Exposure vs Sertraline vs Combination Combat Veterans with PTSD (n=207) 26:30 Medications to Use with Caution (Minimal Positive Evidence in PTSD) 26:47 Notable Novel Mechanism Failures 27:49 Psychedelic-Assisted Psychotherapy 29:02 MDMA-assisted therapy for Severe PTSD: Phase 3 Study (n=90) 29:43 Psilocybin 31:16 Randomized Controlled Trial of IV Ketamine for Chronic PTSD (n=30) 33:58 NIMH Experimental Therapeutics Approach to Interventions 34:19 The "Fast-Fail" Approach to Therapy Develope 35:19 Randomized proof-of-mechanism trial applying the fast-fa approach to evaluating K-opioid antagonism for anhedonia 36:32 Lanicemine: A "Low Trapping" NMDA Receptors Channel Blocker 37:00 Take-home Points • Anxiety disorders are prevalent, chronic, and disabing . Strong support for efficacy of psychopharmacology and evidence-based structured psychotherapy . SSRIs remain first-line choices for major anxiety disorders and PTSD • Non-SSRI alternatives can be considered on individual basis - SNRI, Bupropion, mirtazapine, newer agents (eg, vilazodone, vortioxetine), Anticonvulsants, Antihistamines